News und Analysen
DGAP-Adhoc: BB Biotech AG publishes its interim report
DGAP-Adhoc: BB Biotech AG publishes its interim report
DGAP-News: BB BIOTECH AG: Political factors weigh on biotech equity markets
DGAP-News: BB BIOTECH AG: Political factors weigh on biotech equity markets
DGAP-News: BB BIOTECH AG: Politische Faktoren beeinflussen Biotechaktienmärkte
DGAP-News: BB BIOTECH AG: Politische Faktoren beeinflussen Biotechaktienmärkte
Vifor Pharma nimmt Stellung zu Medienspekulationen
Regulatory News:
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
Vifor führt mit CSL Gespräche über eine mögliche Transaktion. Entsprechende Entscheide sind noch nicht gefallen, es gibt
Annual General Shareholders’ Meeting 2024: Sonova shareholders approve all motions of the Board of Directors
Annual General Shareholders’ Meeting 2024:
Sonova shareholders approve all motions of the Board of Directors
Edison issues review on BB Biotech (BION): A recovering sector with a healthy prognosis
Edison issues review on BB Biotech (BION): A recovering sector with a healthy prognosis
Financial year 2023/24: Sonova ends year on improving trajectory after growth picks up in second half
Financial year 2023/24: Sonova ends year on improving trajectory after growth picks up in second half
EQS-Adhoc: BB Biotech AG publishes its interim report
EQS-Adhoc: BB Biotech AG publishes its interim report
EQS-News: BB Biotech presents solid first-quarter results; biotech stock market impacted by shifting views on interest rates
EQS-News: BB Biotech presents solid first-quarter results; biotech stock market impacted by shifting views on interest rates
EQS-News: Shareholders at BB Biotech AG’s AGM vote in favor of all proposals and approve the dividend of CHF 2.00 per share
EQS-News: Shareholders at BB Biotech AG’s AGM vote in favor of all proposals and approve the dividend of CHF 2.00 per share
EQS-Adhoc: BB Biotech AG publishes its 2023 annual report
EQS-Adhoc: BB Biotech AG publishes its 2023 annual report
EQS-News: Investor interest returns – dividend yield remains high for 2024
EQS-News: Investor interest returns – dividend yield remains high for 2024
EQS-Adhoc: BB Biotech AG publishes financial results for 2023 and changes to the Board of Directors
EQS-Adhoc: BB Biotech AG publishes financial results for 2023 and changes to the Board of Directors
EQS-News: BB Biotech AG: End of year biotech equity market rally – M&A and end of rate hike cycle
EQS-News: BB Biotech AG: End of year biotech equity market rally – M&A and end of rate hike cycle
First half results 2023/24: Substantial acceleration in sales growth expected as temporary headwinds subside
First half results 2023/24: Substantial acceleration in sales growth expected as temporary headwinds subside
Gilbert Achermann to be nominated as a new member of the Sonova Board of Directors
Gilbert Achermann to be nominated as a new member
of the Sonova Board of Directors
EQS-Adhoc: BB Biotech AG publishes its interim report
EQS-Adhoc: BB Biotech AG publishes its interim report
EQS-News: BB BIOTECH AG: Biotech equity markets in flux: the impact of rising bond yields and shifting healthcare policies
EQS-News: BB BIOTECH AG: Biotech equity markets in flux: the impact of rising bond yields and shifting healthcare policies
EQS-News: BB BIOTECH AG: Sector rotation and fund outflows weigh on biotech stocks, but positive developments allow fund raising to strengthen industry
EQS-News: BB BIOTECH AG: Sector rotation and fund outflows weigh on biotech stocks, but positive developments allow fund raising to strengthen industry
EQS-Adhoc: BB Biotech AG publishes its interim report
EQS-Adhoc: BB Biotech AG publishes its interim report
Sonova further extends offering of Sennheiser-branded hearing solutions with All-Day Clear
Sonova further extends offering of Sennheiser-branded
hearing solutions with All-Day Clear
Annual General Shareholders’ Meeting 2023: Sonova shareholders approve all motions of the Board of Directors
Annual General Shareholders’ Meeting 2023:
Sonova shareholders approve all motions of the Board of Directors
Financial year 2022/23: Sonova delivers solid results and preserves profit growth
Financial year 2022/23: Sonova delivers solid results
and preserves profit growth
EQS-News: BB BIOTECH AG: Creating blockbuster drugs using algorithms
EQS-News: BB BIOTECH AG: Creating blockbuster drugs using algorithms